申请人:Lipha, Lyonnaise Industrielle Pharmaceutique
公开号:US05489592A1
公开(公告)日:1996-02-06
Novel 3,4-dihydro-4-oxo-3(prop-2-enyl)-1-phtalazineacetic acids and derivatives of formula (I) ##STR1## in which R.sub.1 R.sub.2 and R.sub.3 are the same or different and stand for H, a halogen or a linear or branched aliphatic, saturated or unsaturated radical, substituted or not by at least one halogen or R.sub.4 residue such as defined below, except when R.sub.4 is H; R.sub.4 and R.sub.5 are the same or different and stand for H, a linear or branched aliphatic radical, saturated or unsaturated, an aryl or heteroaryl radical, said radicals being substituted or not by at least one grouping such as fluorine, chlorine, bromine, methyl or trifluoromethyl, where R.sub.4 and R.sub.5 do not simultaneously denote H; R.sub.6 stands for hydroxy or alkoxy radical; R.sub.7 stands for H, a halogen, a linear or branched aliphatic saturated or unsaturated radical, an alkoxy radical, said radicals being substituted or not by analiphatic or halogenated radical, a nitro group, a substituted or unsubstituted amino group, S(O)n R.sub.8 or a cyano group; n is equal to 0,1 or 2; R.sub.8 is an aliphatic, linear or branched radical, an aryl or heteroaryl radical, an amino radical, said radicals being substituted or not by an aliphatic or halogenated radical. This invention also relates to the optional tautomeric forms of said acids and their pharmaceutically acceptable base addition salts. Also described is a process for preparing said compounds and the drugs containing same.
化合物及其衍生物的化学式(I)为3,4-二氢-4-氧代-3(丙-2-烯基)-1-邻苯二甲酸乙酯及其衍生物,其中R.sub.1、R.sub.2和R.sub.3相同或不同,代表H、卤素或线性或支链的脂肪、饱和或不饱和的基团,通过至少一个卤素或R.sub.4残基进行取代,除非R.sub.4为H;R.sub.4和R.sub.5相同或不同,代表H、线性或支链的脂肪、饱和或不饱和的基团、芳基或杂环基团,这些基团通过至少一个氟、氯、溴、甲基或三氟甲基等基团进行取代,其中R.sub.4和R.sub.5不能同时代表H;R.sub.6代表羟基或烷氧基基团;R.sub.7代表H、卤素、线性或支链的脂肪、饱和或不饱和的基团、烷氧基基团,这些基团通过一个脂肪或卤代基团进行取代,亚硝基、取代或未取代的氨基基团、S(O)nR.sub.8或氰基团;n等于0、1或2;R.sub.8是一个脂肪、线性或支链基团、芳基或杂环基团、氨基基团,这些基团通过一个脂肪或卤代基团进行取代或未取代。本发明还涉及所述酸的可选互变异构体及其药学上可接受的盐。还描述了制备该化合物及含有该化合物的药物的方法。